NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apergy Corporation APY, vTv Therapeutics Inc. VTVT, Arcimoto, Inc. FUV, Lipocine Inc. LPCN, Zealand Pharma A/S ZEAL, and AquaBounty Technologies, Inc. AQB, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
APY DOWNLOAD: http://Capital-Review.com/register/?so=APY
VTVT DOWNLOAD: http://Capital-Review.com/register/?so=VTVT
FUV DOWNLOAD: http://Capital-Review.com/register/?so=FUV
LPCN DOWNLOAD: http://Capital-Review.com/register/?so=LPCN
ZEAL DOWNLOAD: http://Capital-Review.com/register/?so=ZEAL
AQB DOWNLOAD: http://Capital-Review.com/register/?so=AQB
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Apergy Corporation APY, vTv Therapeutics Inc. VTVT, Arcimoto, Inc. FUV, Lipocine Inc. LPCN, Zealand Pharma A/S ZEAL, and AquaBounty Technologies, Inc. AQB on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
APERGY CORPORATION (APY) REPORT OVERVIEW
Apergy's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Apergy reported revenue of $310.33MM vs $265.37MM (up 16.94%) and analysts estimated basic earnings per share $0.60 vs $0.96 (down 37.50%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Apergy reported revenue of $1,216.65MM vs $1,010.47MM (up 20.40%) and analysts estimated basic earnings per share $1.22 vs $1.44 (down 15.28%). Analysts expect earnings to be released on April 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $2.12 and is expected to report on February 17th, 2020.
To read the full Apergy Corporation (APY) report, download it here: http://Capital-Review.com/register/?so=APY
-----------------------------------------
VTV THERAPEUTICS INC. (VTVT) REPORT OVERVIEW
vTv Therapeutics' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, vTv Therapeutics reported revenue of $4.52MM vs $0.23MM (up 1,840.77%) and analysts estimated basic earnings per share -$0.02 vs -$0.44. For the twelve months ended December 31st, 2018 vs December 31st, 2017, vTv Therapeutics reported revenue of $12.43MM vs $0.29MM (up 4,172.85%) and analysts estimated basic earnings per share -$0.69 vs -$1.67. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.30.
To read the full vTv Therapeutics Inc. (VTVT) report, download it here: http://Capital-Review.com/register/?so=VTVT
-----------------------------------------
ARCIMOTO, INC. (FUV) REPORT OVERVIEW
Arcimoto's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Arcimoto reported revenue of $0.00MM vs $0.09MM and analysts estimated basic earnings per share -$0.23 vs -$0.10. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Arcimoto reported revenue of $0.10MM vs $0.13MM (down 25.20%) and analysts estimated basic earnings per share -$0.70 vs -$0.24. Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.13. The estimated EPS forecast for the next fiscal year is -$0.20 and is expected to report on April 3rd, 2020.
To read the full Arcimoto, Inc. (FUV) report, download it here: http://Capital-Review.com/register/?so=FUV
-----------------------------------------
LIPOCINE INC. (LPCN) REPORT OVERVIEW
Lipocine's Recent Financial Performance
Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.13. The estimated EPS forecast for the next fiscal year is $0.68 and is expected to report on March 4th, 2020.
To read the full Lipocine Inc. (LPCN) report, download it here: http://Capital-Review.com/register/?so=LPCN
-----------------------------------------
ZEALAND PHARMA A/S (ZEAL) REPORT OVERVIEW
Zealand Pharma A/S's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Zealand Pharma A/S reported revenue of $1.80MM vs $2.17MM (down 16.89%) and analysts estimated basic earnings per share -$0.53 vs -$0.56. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Zealand Pharma A/S reported revenue of $6.02MM vs $21.23MM (down 71.67%) and analysts estimated basic earnings per share $3.00 vs -$1.48. Analysts expect earnings to be released on May 15th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next fiscal year is -$1.71 and is expected to report on March 5th, 2020.
To read the full Zealand Pharma A/S (ZEAL) report, download it here: http://Capital-Review.com/register/?so=ZEAL
-----------------------------------------
AQUABOUNTY TECHNOLOGIES, INC. (AQB) REPORT OVERVIEW
AquaBounty Technologies' Recent Financial Performance
For the twelve months ended December 31st, 2018 vs December 31st, 2017, AquaBounty Technologies reported revenue of $0.08MM vs $0.05MM (up 58.54%) and analysts estimated basic earnings per share -$0.94 vs -$1.06. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.21.
To read the full AquaBounty Technologies, Inc. (AQB) report, download it here: http://Capital-Review.com/register/?so=AQB
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
